Alemtuzumab or rituximab induction in ABO-incompatible kidney transplantation.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28980

Enrollment

100

Registered

2015-06-02

Start date

2015-04-30

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ABO-incompatible kidney transplantation. Dutch: bloedgroep ABO-incompatible niertransplantatie.

Interventions

observational study

Eligibility

Inclusion criteria

Inclusion criteria: Recipients of an ABO-incompatible kidney transplant aged 18 years or older.

Exclusion criteria

Exclusion criteria: Recipients of an ABO-compatible kidney allograft.

Design outcomes

Primary

Measure	Time frame
-To compare the number of biopsy-proven acute rejections (BPAR) within three months after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.	—

Secondary

Measure	Time frame
- To compare infectious complications after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients. - T compare renal function one year after ABOi kidney transplantation in rituximab versus alemtuzumab treated patients.	—

Contacts

Public ContactA.E. Weerd, de

Internist-nephrologist Erasmus Medical Center Room D-411 Postbus 2040

a.deweerd@erasmusmc.nl0031-10-7034607

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)